Allarity Therapeutics Inc. announced on Wednesday that it has been granted a patent by the U.S. Patent and Trademark Office (USPTO).
The patent covers specific treatment regimens involving Stenoparib, the company's lead drug candidate. These methods are intended for the treatment of ovarian cancer and other types of solid tumors.
This information is based on a report by Rttnews.

